These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 23690408

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [Abstract] [Full Text] [Related]

  • 25. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
    Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC.
    Br J Haematol; 2014 Nov; 167(3):366-75. PubMed ID: 25139740
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J.
    Cancer Invest; 2002 Nov; 20 Suppl 2():45-54. PubMed ID: 12442349
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
    Henk HJ, Teitelbaum A, Perez JR, Kaura S.
    Am J Hematol; 2012 May; 87(5):490-5. PubMed ID: 22454220
    [Abstract] [Full Text] [Related]

  • 30. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ.
    Cancer; 2003 Oct 15; 98(8):1735-44. PubMed ID: 14534891
    [Abstract] [Full Text] [Related]

  • 31. The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.
    Berenson JR.
    Clin Lymphoma Myeloma Leuk; 2012 Feb 15; 12(1):2-4. PubMed ID: 22130220
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
    Henk H, Teitelbaum A, Kaura S.
    Curr Med Res Opin; 2012 Jul 15; 28(7):1119-27. PubMed ID: 22536885
    [Abstract] [Full Text] [Related]

  • 34. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
    Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA.
    Mayo Clin Proc; 2006 Aug 15; 81(8):1047-53. PubMed ID: 16901028
    [Abstract] [Full Text] [Related]

  • 35. [Management of bone lesions in multiple myeloma].
    Hata H, Mitsuya H.
    Gan To Kagaku Ryoho; 2006 Aug 15; 33(8):1072-6. PubMed ID: 16912524
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
    Alegre A, Gironella M, Bailén A, Giraldo P.
    Eur J Haematol; 2014 Mar 15; 92(3):181-8. PubMed ID: 24330023
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.